1. Home
  2. BTAI vs CVKD Comparison

BTAI vs CVKD Comparison

Compare BTAI & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BTAI
  • CVKD
  • Stock Information
  • Founded
  • BTAI 2017
  • CVKD 2022
  • Country
  • BTAI United States
  • CVKD United States
  • Employees
  • BTAI N/A
  • CVKD N/A
  • Industry
  • BTAI Biotechnology: Pharmaceutical Preparations
  • CVKD Medicinal Chemicals and Botanical Products
  • Sector
  • BTAI Health Care
  • CVKD Health Care
  • Exchange
  • BTAI Nasdaq
  • CVKD Nasdaq
  • Market Cap
  • BTAI 18.1M
  • CVKD 20.8M
  • IPO Year
  • BTAI 2018
  • CVKD 2023
  • Fundamental
  • Price
  • BTAI $0.34
  • CVKD $17.40
  • Analyst Decision
  • BTAI Buy
  • CVKD Strong Buy
  • Analyst Count
  • BTAI 4
  • CVKD 1
  • Target Price
  • BTAI $2.81
  • CVKD $32.00
  • AVG Volume (30 Days)
  • BTAI 1.3M
  • CVKD 69.6K
  • Earning Date
  • BTAI 03-11-2025
  • CVKD 03-10-2025
  • Dividend Yield
  • BTAI N/A
  • CVKD N/A
  • EPS Growth
  • BTAI N/A
  • CVKD N/A
  • EPS
  • BTAI N/A
  • CVKD N/A
  • Revenue
  • BTAI $2,276,000.00
  • CVKD N/A
  • Revenue This Year
  • BTAI $131.23
  • CVKD N/A
  • Revenue Next Year
  • BTAI $45.79
  • CVKD N/A
  • P/E Ratio
  • BTAI N/A
  • CVKD N/A
  • Revenue Growth
  • BTAI 83.25
  • CVKD N/A
  • 52 Week Low
  • BTAI $0.30
  • CVKD $5.40
  • 52 Week High
  • BTAI $4.17
  • CVKD $32.55
  • Technical
  • Relative Strength Index (RSI)
  • BTAI 42.14
  • CVKD 58.52
  • Support Level
  • BTAI $0.33
  • CVKD $15.56
  • Resistance Level
  • BTAI $0.39
  • CVKD $18.50
  • Average True Range (ATR)
  • BTAI 0.06
  • CVKD 1.43
  • MACD
  • BTAI -0.00
  • CVKD 0.19
  • Stochastic Oscillator
  • BTAI 9.27
  • CVKD 74.33

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.

Share on Social Networks: